MEK inhibitor monotherapy has activity in BRAF V600 wild-type, NRAS Q61R/K/L mutant melanoma and BRAF V600 wild-type/NRAS Q61R/K/L wild-type melanoma but is associated with considerable treatment-limiting skin toxicity. This evidence concerns the gene MAP2K7 and melanoma.